Omega Diagnostics Group PLC
10 April 2008
Omega Diagnostics Group PLC
('Omega' or 'the Group)
Trading Update
Omega, the AIM listed medical diagnostics company, announces that trading for
the year ended 31st March 2008 was in line with market expectations with
turnover showing an increase for the year of circa 70% over the previous year
(year ended 31st March 2007: £2.03m).
The increase in turnover follows the acquisition of Genesis Diagnostics Ltd and
Cambridge Nutritional Sciences Ltd in September 2007 which contributed around
68% of the growth, and organic growth of around 2%.
The directors are confident for the prospects of the Group for the new financial
year and the Group will announce its results for the year ended 31st March 2008
during July 2008.
Contacts:
Omega Diagnostics Group PLC Landsbanki Securities Parkgreen Communications
(UK) Limited
Andrew Shepherd, Chief Executive Thilo Hoffmann Ben Knowles
Kieron Harbinson, Finance Director
Simon Brown
Tel: 01259 763030 020 7426 9000 Tel: 020 7479 7933
www.omegadiagnostics.com Mob: 07900 346 978
ben.knowles@parkgreenmedia.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.